Cargando…

Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study

PURPOSE: This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy. MATERIALS AND METHODS: We performed a case-control...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Haeyoung, Park, Won, Yu, Jeong Il, Choi, Doo Ho, Huh, Seung Jae, Kim, Yeon-Joo, Lee, Eun Sook, Lee, Keun Seok, Kang, Han-Sung, Park, In Hae, Shin, Kyung Hwan, Wee, Chan Woo, Kim, Kyubo, Park, Kyung Ran, Kim, Yong Bae, Ahn, Sung Ja, Lee, Jong Hoon, Kim, Jin Hee, Chun, Mison, Lee, Hyung-Sik, Kim, Jung Soo, Cha, Jihye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654147/
https://www.ncbi.nlm.nih.gov/pubmed/28052649
http://dx.doi.org/10.4143/crt.2016.382
Descripción
Sumario:PURPOSE: This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy. MATERIALS AND METHODS: We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups. RESULTS: A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI. CONCLUSION: We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.